Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
VK2735 was well tolerated, with mostly mild/moderate adverse events and low discontinuations
The results were striking: Nearly half cut their pain days in half
Animal Model Evidence The systemic evidence base is entirely preclinical: Pulmonary fibrosis (mouse model): Intraperitoneal GHK-Cu at 0.2-20 micrograms/g/day protected against bleomycin-induced lung fibrosis by inhibiting TGF-beta1/Smad signaling and reducing oxidative stress (PMID 31809714)
April 9, 2026 Not for human consumption
In addition, it has a drug-affinity complex (DAC) attached, enhancing its half-life to up to 8 days [25, 26]
US$ 21.72
US$ 24.55
US$ 20.64
